Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript
Rafael Holdings, Inc. (RFL) discussed the topline results of the Phase III TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C, according to a Seeking Alpha transcript of the discussion.
Why it matters — A watcher of RFL would care because the Phase III results of its Trappsol Cyclo candidate represent a key clinical milestone for the company's pipeline.